Comments
Natco Pharma on Saturday reported a 21.66 per cent rise in its consolidated net profit to Rs 17.07 crore for the quarter ended June 30, 2012 on account of robust sales in formulations segment.
The company had posted a net profit of Rs 14.03 crore for the corresponding quarter previous fiscal, Natco Pharma said in a filing to BSE.
Consolidated net sales of the company for the quarter under consideration also rose to Rs 134.47 crore from Rs 113.18 crore for the same period year ago.
The formulations sales of the company stood at Rs 70.56 crore for the first quarter this fiscal as against Rs 53.28 crore for the corresponding quarter last fiscal.
In March this year Natco Pharma was allowed to sell it’s version of Bayer’s Nexavar at Rs 8,880 for a month’s dose as compared to Rs 2.8 lakh by Bayer after India Patents Office invoked compulsory licence for the first time in the country.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.